[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053364":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":57,"collaborators":59,"id":63,"slug":31,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":31,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":31,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":39,"whyStopped":31,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Johns Hopkins University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Atorvastatin 40 mg","EXPERIMENTAL","Participants receive 40 mg atorvastatin orally daily in the evening.",[13],"Drug: Atorvastatin Oral Tablet",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Atorvastatin Oral Tablet","Atorvastatin pill 40 mg to be taken every night",[9],[21],"Lipitor oral tablet",[23],{"name":24,"affiliation":5,"role":25},"Paul Rosenberg, MD","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Samantha Horn","CONTACT","410-550-9020",null,"shorn8@jhmi.edu",{"name":34,"role":29,"phone":30,"phoneExt":31,"email":35},"Ritu Agarwal","ragarw19@jhmi.edu",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Johns Hopkins University, Bayview Medical Center","RECRUITING","Baltimore","Maryland","21224","United States",{"type":45,"coordinates":46},"Point",[47,48],-76.61219,39.29038,{"lat":48,"lon":47},[51,52,53,54],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},{"name":34,"role":29,"phone":30,"phoneExt":31,"email":35},{"name":24,"role":25,"phone":31,"phoneExt":31,"email":31},{"name":55,"role":56,"phone":31,"phoneExt":31,"email":31},"Sevil Yasar, MD, PhD","SUB_INVESTIGATOR",{"type":58,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[60],{"name":61,"class":62},"The Richman Family Precision Medicine Center of Excellence in Alzheimer Disease","UNKNOWN","100053364",false,"NCT04765137","Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)","Targeting Cerebrovascular Reactivity for Precision Medicine: Pilot Trial of Atorvastatin","Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors:\n\n* MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.\n* Memory, processing speed, executive function, language - cognitive scores \\> 1.5 standard deviations below age-education norms.\n* Not demented by history.\n* Not taking statins currently or in the last 6 months.\n* Cognitive\u002Ffunctional impairment not likely due to another neurological disease or delirium.\n\nExclusion Criteria:\n\n* Taking a statin currently or have taken a statin in the last 6 months.\n* Contraindications to taking a statin.\n* Transplant patient taking cyclosporine.\n* Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).\n* Diagnosis of dementia by history.\n* Current diagnosis of substance abuse.\n* History of stroke or myocardial infarction in past 6 months.\n* History of HIV.",true,"ALL","60 Years","95 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.",[81],"Mild Cognitive Impairment",[83],"Cerebral Vascular Reactivity","2026-07-09",{"date":86,"type":87},"2026-07-13","ACTUAL",{"date":89,"type":87},"2021-05-21",{"date":91,"type":75},"2027-12-31",{"name":5,"class":6},1]